摘要
1966年 db基因发现后,其被确定为在db/db小鼠血液输送过程中产生的过多的饱足因子,但未对此作出回应。db/db小鼠模型被2型糖尿病广泛应用,其在人类疾病中具有表型复制特征并能引发多种并发症包括肥胖,葡萄糖耐量进行性恶化,高血压和高脂血症等。与非糖尿病组相比,db/db小鼠模型组有肝糖原水平持续升高现象,最有可能是由于摄食过多。在透射电子显微镜下,肝糖原通常呈现出一种复合的菜花状形态,大的“α颗粒”(在一定范围的大小)组成较小的“β颗粒”并结合在一起。新研究已探讨了肝糖原分子的大小分布,发现在db/db小鼠模型中,α颗粒比健康小鼠中更易破碎,并能容易地分裂为小的β颗粒。有证据表明,较小的糖原颗粒与糖原磷酸化酶—参与糖原降解的关键酶结合更紧密,并在体外降解更迅速。因此,无法形成稳定的大糖原α颗粒,由此预测将导致葡萄糖的降解更快,受控更少,但其对血糖控制的影响仍有待进一步充分阐明。然而,本文旨在“抢救”更易碎的糖尿病肝糖原以减少2型糖尿病中肝葡萄糖的输出,为其提供一个潜在的治疗靶点。
关键词: Db/db
图形摘要
Current Drug Targets
Title:Impairment of Liver Glycogen Storage in the db/db Animal Model of Type 2 Diabetes: A Potential Target for Future Therapeutics?
Volume: 16 Issue: 10
Author(s): Mitchell A. Sullivan, Brooke E. Harcourt, Ping Xu, Josephine M. Forbes and Robert G. Gilbert
Affiliation:
关键词: Db/db
摘要: After the discovery of the db gene in 1966, it was determined that a blood-borne satiety factor was produced excessively, but was not responded to, in db/db mice. This model for type 2 diabetes is widely used since it phenocopies human disease and its co-morbidities including obesity, progressive deterioration in glucose tolerance, hypertension and hyperlipidaemia. Db/db mice, unlike their non-diabetic controls, have consistently elevated levels of liver glycogen, most likely due to hyperphagia. In transmission electron micrographs, liver glycogen usually shows a composite cauliflower-like morphology of large “α particles” (with a wide range of sizes) made up of smaller “β particles” bound together. New studies have explored the size distribution of liver glycogen molecules and found that α particles in db/db mice are more chemically fragile than those in healthy mice, and can readily break apart to smaller β particles. There is evidence that smaller glycogen particles have a higher association with glycogen phosphorylase, a key enzyme involved in glycogen degradation, as well as being degraded more rapidly in vitro; therefore the inability to form stable large glycogen α particles is predicted to result in a faster, less controlled degradation into glucose. The implications of this for glycaemic control remain to be fully elucidated. However, “rescuing” the more fragile diabetic glycogen to decrease hepatic glucose output in type 2 diabetes, may provide a potential therapeutic target which is the subject of this review.
Export Options
About this article
Cite this article as:
Mitchell A. Sullivan, Brooke E. Harcourt, Ping Xu, Josephine M. Forbes and Robert G. Gilbert , Impairment of Liver Glycogen Storage in the db/db Animal Model of Type 2 Diabetes: A Potential Target for Future Therapeutics?, Current Drug Targets 2015; 16 (10) . https://dx.doi.org/10.2174/1389450116666150727123115
DOI https://dx.doi.org/10.2174/1389450116666150727123115 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Genetics and Genomics of Systemic Sclerosis: An Update and Review
Current Rheumatology Reviews Therapeutic Potential of Voltage Gated Calcium Channels
Mini-Reviews in Medicinal Chemistry Indoxyl Sulfate: A Candidate Target for the Prevention and Treatment of Cardiovascular Disease in Chronic Kidney Disease
Current Drug Targets Complementary Role of Herbal Medicine and Exercise in Cardiovascular Disease Prevention and Management: A Review of Evidence
Current Pharmaceutical Design Angiotensin II: Role in Skeletal Muscle Atrophy
Current Protein & Peptide Science Adipose Tissue: The Link Between Obesity and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Use of Diverse Chemometric and Validation Methods to Accurately Predict Human Urotensin-II Receptor Antagonist Activity
Current Computer-Aided Drug Design Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design Molecular Mechanisms of Impaired Endothelial Function Associated with Insulin Resistance
Current Drug Targets - Cardiovascular & Hematological Disorders Dietary Approaches and Alternative Therapies for Polycystic Ovary Syndrome
Current Nutrition & Food Science Vitamin D Levels Correlate with Metabolic Syndrome Criteria in Algerian Patients: The Ex-vivo Immunomodulatory Effect of α, 25 Dihydroxyvitamin D3
Endocrine, Metabolic & Immune Disorders - Drug Targets Unfolded Protein Response as a Therapeutic Target in Cardiovascular Disease
Current Topics in Medicinal Chemistry The Effects of Interleukin-10 on the Expression of Fas and FasL in Rat Hepatic Stellate Cells
Medicinal Chemistry The HGF/c-Met Receptor System Under Pathological Conditions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Vascular Risk Factors and Lesions of Vascular Nature in Magnetic Resonance as Predictors of Progression to Dementia in Patients with Mild Cognitive Impairment
Current Alzheimer Research Hepatic Injury to the Newborn Liver Due to Drugs
Current Pharmaceutical Design Retinal Protein O-GlcNAcylation and the Ocular Renin-angiotensin System: Signaling Cross-roads in Diabetic Retinopathy
Current Diabetes Reviews Editorial (Thematic Issue: “Amniotic Fluid Embolism: Novel Biomarkers for Future Diagnostic Investigation and Therapy”)
Current Pharmaceutical Biotechnology Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment
Current Diabetes Reviews